Lucius LuciRevu Revumenib 110mg

Product Information

• Product name: LuciRevu Revumenib 110mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Revumenib
• Current strength: 110mg
• SKU: LU-ITEM-151
• Site category: acute myeloid leukemia (AML), other cancer

Product Summary

LuciRevu Revumenib 110mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Revumenib is the active ingredient used for this product page. Public prescribing information for Revumenib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Revumenib is a menin inhibitor that blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of wild-type KMT2A or KMT2A fusion proteins with menin is involved in NPM1 mutated acute myeloid leukemias and KMT2A – rearranged acute leukemias, respectively, through activation of a leukemogenic transcriptional pathway.

Reference Indications

Revumenib is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. Relapsed or Refractory Acute Leukemia Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older.

Reference Dosage and Administration

Recommended dosage of Revumenib varies by patient weight and concomitant use of strong CYP3A4 inhibitors. Administer Revumenib orally twice daily fasted or with a low-fat meal at approximately the same time each day.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: DIFFERENTIATION SYNDROME, QTc PROLONGATION and TORSADES DE POINTES Differentiation syndrome, which can be fatal, has occurred with Revumenib. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. QTc prolongation and Torsades de Pointes have occurred in patients receiving Revumenib. Correct hypokalemia and hypomagnesemia prior to and during treatment. Do not initiate Revumenib in patients with QTcF > 450 msec. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue Revumenib.

Common Adverse Reactions and Monitoring

The safety of Revumenib reflects exposure in 241 patients (207 adult and 34 pediatric patients) with relapsed or refractory (R/R) acute leukemia with a KMT2A translocation or an NPM1 mutation treated with Revumenib at a dose approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor . The median duration of exposure to Revumenib was 2.5 months (range < 1 to 40 months), and 10% of patients were exposed for more than 6 months.

Drug Interactions and Special Populations

Strong CYP3A4 Inhibitors: Reduce the Revumenib dose. ( 2.2 , 7.1 ) Strong or moderate CYP3A4 Inducers: Avoid concomitant use with Revumenib. QTc Prolonging Drugs: Avoid concomitant use with Revumenib. If concomitant use is unavoidable, monitor patients more frequently for QTc interval prolongation. ( 5.2 , 7.1 ) 7.1 Effect of Other Drugs on Revumenib Strong CYP3A4 Inhibitors If concomitant use of strong CYP3A4 inhibitors is required, reduce the Revumenib dosage . Revumenib is primarily metabolized by CYP3A4 . Strong or Moderate CYP3A4 Inducers Avoid concomitant use with strong or moderate CYP3A4 inducers. Revumenib is primarily metabolized by CYP3A4 .

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Revuforj public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.